Vinorelbine is a vesicant associated with extra-vasation hazards and injection site reactions, which can be alleviated by shortening of infusion time and flushing of intravenous fluid. A critical review of the current evidence showed that the optimal administration is to flush ≥75-124 mL of intravenous fluid after vinorelbine infusion. In travenous push administration over 1-2 min does not seem to offer significant improvement over rapid intravenous infusion over 6-10 min.
B. C. Cancer Agency Provincial Systemic Therapy Program. Provincial Systemic Therapy Program Policy III-20: prevention and management of extravasation of chemotherapy. Vancouver, BC: BC Cancer Agency, 1 February 2004.
Vassilomanolakis M, Koumakis G, Barbounis V, et al.Prevention of vinorelbine phlebitis with cimetidine. A two-step design study. Support Care Cancer2001; 9: 108-111.
5.
Ginopoulos P, Mastronikolis NS, Karana A, et al.Use of dexamethasone in the management of phlebitis caused by intravenous administration of vinorelbine (navelbine). Med Sci Res1998; 26: 397-398.
6.
Mare M, Maisano R, Caristi N, et al.Venous damage prevention by defibrotide in vinorelbine-treated patients. Support Care Cancer2003; 11: 593-596.
7.
Fossella F, Pereira JR, von Pawel J, et al.Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol2003; 21: 3016-3024.
8.
Scagliotti GV, De Marinis F, Rinaldi M, et al.Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol2002; 20: 4285-4291.
9.
Yoh K, Niho S, Goto K, et al.A randomized trial of 6-minutes drip infusion versus 1-minute bolus injection of vinorelbine (VNR) for the control of drug induced-phlebitis. J Clin Oncol (Meeting Abstracts)2004; 22: 8117-8117.
